anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Dabrafenib
Trial phase: Not Applicable
ATC code: L01EC02 | L01XE23
SMILES: CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.

GSK2118436: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed papillary thyroid carcinoma, including its variants, such as tall cell PTC or poorly differentiated thyroid carcinoma, that is metastatic or unresectable AND harbors a BRAF V600E mutation
Evaluable disease, as defined by at least one lesion that can be accurately measured in at least one dimension on CT scan or ultrasound, if present in the neck
Radioiodine-refractory disease
Life expectancy > 6 months
Able to swallow and retain oral medication
Normal organ and marrow function

Exclusion Criteria:

Pregnant or breastfeeding
Previous treatment with a specific BRAF or MEK inhibitor
Receiving any other study agents
Known brain metastases
History of allergic reactions attributed to compounds of similar chemical or biologic composition to GSK2118436, bovine TSH, mannitol or iodine
Active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs
History of known glucose-6-phosphate dehyrogenase (G6PD) deficiency
Corrected QT interval >/= 480 msecs; history of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks; Class II, III, or IV heart failure, abnormal cardiac valve morphology; or history of known cardiac arrhythmias
Taking herbal remedies
Subjects with significant symptoms from their thyroid cancer, or have a large burden of rapidly progressive iodine-refractory PTC who are in need of other systemic therapy, as judged by their treating physician
Uncontrolled current illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements
History of a different malignancy unless disease-free for at least 5 years and deemed to be at low risk for recurrence
HIV-positive on combination antiretroviral therapy
Intervention: Lisinopril
Trial phase: Phase 4
ATC code: C09AA03 | C09BA03 | C09BB03 | C10BX07
SMILES: NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Active group

Lisinopril: Lisinopril 20mg QD x 24 weeks
Eligibility criteria:
Inclusion Criteria include:

Stable HAART with maintenance of plasma HIV RNA levels below level of detection (< 40-75 copies/mL) for ≥ 12 months
> 90% adherence to HAART within preceding 30 days

Exclusion Criteria include:

Screening systolic blood pressure < 110mm Hg or diastolic blood pressure < 60mm Hg
Current use of any ACE inhibitor, angiotensin receptor blocker, or aldosterone antagonist
Known diabetes mellitus or cardiovascular/kidney/collagen vascular disease
Pregnant/breastfeeding women.
Intervention: Dexmedetomidine
Trial phase: Phase 4
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 140
Group description: Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.

Dexmedetomidine: Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).

All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider.
Eligibility criteria:
Inclusion Criteria:

ASA I or II (American Society of Anesthesiology classification ASA I means patients without systemic disease, ASA II means patients with one controlled systemic medical disease eg: Diabetes, Hypertension.)
Between the ages of 1 and 10 years
Undergoing BMT under general anesthesia.

Exclusion Criteria:

ASA III or higher (Patients with 2 or more medical systemic disease that is not under control, eg: uncontrolled Diabetes)
Congenital diseases
Coagulation disorders
Known allergic reaction to dexmedetomidine
Serious preexisting impairment of respiratory, cardiovascular, hepatic, renal, neurological or endocrine functions
Severe upper airway infection
Predicted difficult airway
Preexisting psychiatric disorders
Intervention: Hydroxychloroquine
Trial phase: Phase 2
ATC code: P01BA02
SMILES: CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Patients with CVD and CKD will be randomized to either hydroxychloroquine (HCQ) or placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)

Hydroxychloroquine: 200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
Eligibility criteria:
Inclusion Criteria:

Measured stage IV proteinuric chronic kidney disease with an estimated Modification of Diet in Renal Disease (MDRD) GFR (eGFR) of 18 to 35 ml/min.
Current or history of documented proteinuria of more than or equal to 300 mg/dL in 24 hours or a spot urine protein to creatinine ratio of greater than 0.3 ug/mg.
Not on dialysis.
Ages 18 to 80 years, both sexes, all races and ethnicities

Exclusion Criteria:

glucose-6-phosphate dehydrogenase (G6PD) deficiency or known hypersensitivity to 4-aminoquinoline compounds (such as chloroquine or hydroxychloroquine).
Abnormal liver functions; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 2.5 times the normal or international normalized ratio (INR) without being anti-coagulated greater than 1.4.
Known chronic active infections like HIV, Hepatitis B or Hepatitis C positive, chronic osteomyelitis etc.
Recent serious infection including Pneumonia requiring hospitalization, meningitis, septicemia in the 2 months prior to screening.
Active or recently treated (< 1 year in remission) malignancy or systemic inflammatory diseases (Patients with localized squamous cell carcinoma of the skin are eligible).
Pregnancy, breastfeeding or planning to become pregnant during the course of the study.
Use of systemic corticosteroids or other immunosuppression within last 3 months (acute course of steroid for a gouty arthritis or chronic obstructive pulmonary disease (COPD) is eligible if > 1 month ago).
History of prolonged corrected QT interval > 450.
Inability to attend or comply with treatment or follow-up scheduling.
Life expectancy less than 6 months or uncontrolled congestive heart failure (CHF) (defined as more than 2 admissions in prior 6 months).
Any other condition the PI determines may put the research subject in jeopardy during the course of the study.
Intervention: Methylene Blue
Trial phase: Not Applicable
ATC code: V03AB17 | V04CG05
SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure

Methylene Blue: 20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
Eligibility criteria:
Inclusion Criteria:

Male or Female of all races
Older than 18 years old
Scheduled for an elective surgical procedure under general anesthesia for no less than 2hr and no more than 12hr with planned endotracheal intubation via the oral route
Willing and able to give informed consent for participation in the study
Anticipated extubation at the conclusion of general anesthesia in the operating room and prior to admission to the PACU
Expected hospital stay of greater than or equal to 23hrs

Exclusion Criteria:

Preexisting acute respiratory illness requiring antibiotic treatment within the two weeks prior to surgery
Temperature of over 101 degrees F (38.3 C) at time of scheduled surgery
Surgical requirement for naso-tracheal intubation
Patients undergoing surgical procedures directly on the lungs, trachea, or airways
Presence of tracheostomy
History of allergic reaction to methylene blue
Methemoglobinemia, glucose-6-phosphate (G6PD) deficiency
Renal insufficiency or failure
Requirement for prolonged intubation and/or ventilation beyond the point of PACU admission
Intraoperative use of nitrous oxide, to avoid the increase in cuff pressure due to diffusion of gas over time
Psychiatric drugs of the following classifications: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).
Patients younger than 18 years of age
Prone positioning during surgery
Pregnant or lactating women based on standardized preoperative screening protocols
Legally detained prisoner status
Unwilling or unable to give informed consent for participation in the study
Intervention: Methylene Blue
Trial phase: Not Applicable
ATC code: V03AB17 | V04CG05
SMILES: CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.[Cl-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure

Methylene Blue: 20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
Eligibility criteria:
Inclusion Criteria:

Male or Female of all races
Older than 18 years old
Scheduled for an elective surgical procedure under general anesthesia for no less than 2hr and no more than 12hr with planned endotracheal intubation via the oral route
Willing and able to give informed consent for participation in the study
Anticipated extubation at the conclusion of general anesthesia in the operating room and prior to admission to the PACU
Expected hospital stay of greater than or equal to 23hrs

Exclusion Criteria:

Preexisting acute respiratory illness requiring antibiotic treatment within the two weeks prior to surgery
Temperature of over 101 degrees F (38.3 C) at time of scheduled surgery
Surgical requirement for naso-tracheal intubation
Patients undergoing surgical procedures directly on the lungs, trachea, or airways
Presence of tracheostomy
History of allergic reaction to methylene blue
Methemoglobinemia, glucose-6-phosphate (G6PD) deficiency
Renal insufficiency or failure
Requirement for prolonged intubation and/or ventilation beyond the point of PACU admission
Intraoperative use of nitrous oxide, to avoid the increase in cuff pressure due to diffusion of gas over time
Psychiatric drugs of the following classifications: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).
Patients younger than 18 years of age
Prone positioning during surgery
Pregnant or lactating women based on standardized preoperative screening protocols
Legally detained prisoner status
Unwilling or unable to give informed consent for participation in the study
Intervention: 2,4-Pentadienoic acid, 3-methyl-5-((1S,2S)-2-methyl-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)cyclopropyl)-, (2E,4E)-
Trial phase: Phase 2
SMILES: CC(C=CC1CC1(C)c1ccc2c(c1)C(C)(C)CCC2(C)C)=CC(=O)O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.

NRX 194204: NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
Eligibility criteria:
Inclusion Criteria:

Histologically or cytologically confirmed prostate cancer
Documented progression on at least one prior hormone treatment, AND at least one taxane based chemotherapy regimen, or patient's refusal of chemotherapy treatment
Male, Age > 18 years
ECOG (Eastern Cooperative Oncology Group) performance score of 0-2
Adequate bone marrow, renal and hepatic function
Men of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafter

Exclusion Criteria:

Prior treatment with NRX 194204 or bexarotene (Targretin)
Presence of parenchymal brain metastases
History of prior malignancy within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder or other stage I or stage II cancer in complete remission for at least 12 months
Patients with a history of unstable or newly diagnosed angina pectoris, documented history of current serious arrhythmia or congestive heart failure or myocardial infarction within 6 months of enrollment
Known HIV or hepatitis B or C infection
Life expectancy < 3 months
Patients with any history of thyroid disease, pituitary disease or treatment with thyroid replacement hormone
Patients with a history of pancreatitis or at significant risk of developing pancreatitis
Intervention: Valganciclovir
Trial phase: Phase 4
ATC code: J05AB14
SMILES: CC(C)C(N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: 900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.
Eligibility criteria:
Inclusion Criteria:

Be > / = 18 years of age.
Have negative Cytomegalovirus (CMV) serology (confirmed within 6 months of transplant) and receive a liver from a donor with positive CMV serology (R-/D+).
Have received their first orthotopic liver transplant (the transplanted liver may be deceased donor or live donor graft) within 10 days prior.
Have absolute neutrophil count > 1000/µL at randomization.

- If female, and not postmenopausal or surgically sterile, must have negative pregnancy test (serum or urine) within 48 hours prior to randomization and must also agree to use medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence for 100 days after randomization and 3 months after valganciclovir cessation.

-- If male, and has not had a vasectomy, he must agree to practice barrier method of contraception for 100 days after randomization and 3 months after valganciclovir cessation.

Subject or legally authorized representative has provided written informed consent.

Exclusion Criteria:

Currently enrolled in any interventional trial of an investigational therapeutic agent unless co-enrollment has been approved by study Principal Investigators (PIs) and the DMID prior to enrollment.
Have hypersensitivity to acyclovir, ganciclovir or valganciclovir.
Be breast-feeding mother.
Have known Human immunodeficiency virus (HIV) infection (based on testing performed during the transplant evaluation process).
Be undergoing multi organ transplant or have undergone prior organ transplant.
Have expected life expectancy of less than 72 hours.
Intervention: Valganciclovir
Trial phase: Phase 4
ATC code: J05AB14
SMILES: CC(C)C(N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 105
Group description: 900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.
Eligibility criteria:
Inclusion Criteria:

Be > / = 18 years of age.
Have negative Cytomegalovirus (CMV) serology (confirmed within 6 months of transplant) and receive a liver from a donor with positive CMV serology (R-/D+).
Have received their first orthotopic liver transplant (the transplanted liver may be deceased donor or live donor graft) within 10 days prior.
Have absolute neutrophil count > 1000/µL at randomization.

- If female, and not postmenopausal or surgically sterile, must have negative pregnancy test (serum or urine) within 48 hours prior to randomization and must also agree to use medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence for 100 days after randomization and 3 months after valganciclovir cessation.

-- If male, and has not had a vasectomy, he must agree to practice barrier method of contraception for 100 days after randomization and 3 months after valganciclovir cessation.

Subject or legally authorized representative has provided written informed consent.

Exclusion Criteria:

Currently enrolled in any interventional trial of an investigational therapeutic agent unless co-enrollment has been approved by study Principal Investigators (PIs) and the DMID prior to enrollment.
Have hypersensitivity to acyclovir, ganciclovir or valganciclovir.
Be breast-feeding mother.
Have known Human immunodeficiency virus (HIV) infection (based on testing performed during the transplant evaluation process).
Be undergoing multi organ transplant or have undergone prior organ transplant.
Have expected life expectancy of less than 72 hours.
Intervention: AMINOSALICYLIC ACID
Trial phase: Phase 3
ATC code: J04AA01 | J04AA02 | J04AA03
SMILES: Nc1ccc(C(=O)O)c(O)c1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 20
Group description: intravenous lipid: intravenous given daily for 6 weeks
Eligibility criteria:
Inclusion Criteria:

All neonates ≥ 34 weeks gestational age with major GI surgical disorders (Gastroschisis, omphalocele, volvulus, trachea-esophageal fistula, duodenal atresia, jejunal atresia, ileal atresia, hirschsprung's disease, anorectal malformation, intestinal obstruction, and GI perforations) requiring surgery admitted to our NICU within first 72 hours will be eligible for this study

Exclusion Criteria:

If does not need TPN by 72 hours;
Direct hyperbilirubinemia within the first 72 hours after birth;
TORCH infections (Toxoplasmosis, CMV, Herpes, Rubella, HIV, etc);
Biliary tract disorders leading to direct hyperbilirubinemia;
Known metabolic disorders that may be associated with direct hyperbilirubinemia- such as Galactosemia, α-1 antitrypsin deficiency, etc
Intervention: Lurasidone
Trial phase: Phase 3
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 191
Group description: Lurasidone 40 - 80mg flexible dose

Lurasidone: Lurasidone 40-80 mg taken orally taken once daily
Eligibility criteria:
Inclusion Criteria:

Subject has agreed to participate by providing written informed consent.
Subject will be eligible to participate if one of the following criteria is met:
Subject has completed the 28-week double-blind phase of study D1050238
Subject has experienced a protocol-defined relapse event during the double- blind phase in study D1050238
Subject is participating in the open-label or double-blind phase of study D1050238 if/when study D1050238 is terminated by the sponsor.
Subject has completed all required assessments on the final study visit (Study Visit Number 42) in study D1050238.
Subject is judged by the Investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator.

Exclusion Criteria:

Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at the extension baseline visit (Study Visit Number 42 in study D1050238). Subjects who answer "yes" to this question must be referred by the Investigator for appropriate follow-up evaluation and treatment.
Subject tests positive for drugs of abuse or is suspected of current alcohol abuse at the extension baseline visit (Study Visit Number 42 in study D1050238). In the event a subject tests positive for cannabinoids, the Investigator will evaluate the subject's ability to abstain from cannabis during the study.
Intervention: Ergocalciferol
Trial phase: Phase 4
ATC code: A11CC01
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Vitamin D Treatment Group

Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks
Eligibility criteria:
Inclusion Criteria:

Female gender (refer to section 4)
Age > 18, using an effective form of contraception (refer to section 4)
An indication to be on statin therapy
Moderate to severe myopathic pain while on Simvastatin
Serum CK level < 10 x ULN
Vitamin 25 OH D level < 30 ng/mL (as secondary hyperparathyroidism is triggered below this level)1
English speaking patients only
Myopathic pain that cannot be attributed to other medical conditions
Continue a statin within the CYP3A4 family
Competent to give informed consent

Exclusion Criteria:

Clinical diagnosis of overt vitamin D deficiency: osteomalacia, rickets, hypocalcemia, hypophosphatemia
Already taking Vitamin D supplements > 1000 IU/day
Serum creatinine > 2.2 mg/dL within last 6 months
AST/ALT > 3 x ULN of the local reference range
Serum CK level > 10 x ULN
Systolic blood pressure < 100 mmHg
Albumin adjusted calcium > 2.55 mmol/L or < 2.20 mmol/L
Renal osteodystrophy
Malabsorption syndrome
Metastatic malignancy
Transplant recipients
A co-existent diagnosis of renal calculi within the previous 6 months
A co-existent diagnosis of primary hyperparathyroidism within the previous 6 months
Recent therapy with corticosteroids within the previous 6 months
Currently consuming Digoxin, as usage increases risk of hypercalcemia
Lactating women